Table 1 Participants' characteristics at baseline
From: Atrial fibrillation incidence and outcomes in two cohorts of octogenarians: LiLACS NZ
Whole sample, n = 877 (col %) | Māori, n = 379 (col %) | Non-Māori, n = 498 (col %) | |
|---|---|---|---|
Age, mean (SD) | 83.8 (2.1) | 82.7 (2.8) | 84.6 (0.6) |
Gender, | |||
Men | 398 (45%) | 162 (42.7%) | 233 (46.8%) |
Women | 482 (55%) | 217 (57.3%) | 265 (53.2%) |
Education | |||
- Primary | 189 (22%) | 107 (28.9%) | 82 (16.8%) |
- Secondary | 497 (57.9%) | 211 (57.0%) | 286 (58.5%) |
- Trade or tertiary | 173 (20.1%) | 52 (14.4%) | 121 (24.7%) |
NZ Dep Index | |||
- 1 – 4 (low deprivation) | 157 (17.9%) | 44 (11.6%) | 113 (22.7%) |
- 5—7 | 266 (30.3%) | 86 (22.7%) | 180 (36.1%) |
- 8—10 | 454 (51.8%) | 249 (65.7%) | 205 (41.2%) |
Smoking | |||
- Never a smoker | 414 (47.9%) | 162 (43.8%) | 252 (50.9%) |
- Past (stopped more than 12 mths) | 388 (44.9%) | 169 (45.7%) | 219 (44.2%) |
- Current | 63 (7.3%) | 39 (10.5%) | 24 (4.8%) |
Fasting glucose (mmol/L), median (IQR) | 5.3 (0.9) | 5.4 (1.1) | 5.2 (0.9) |
FT4 (pmol/L), median (IQR) | 15.2 (2.8) | 15.2 (2.5) | 15.1 (2.9) |
TSH (mIU/L), median (IQR) | 2.4 (2.0) | 2.05 (1.9) | 2.5 (1.9) |
SBP/DBP, mean (SD) | 150 (23) / 81 (13) | 145 (22) / 80 (13) | 152 (23) / 82 (12) |
AF at baseline | 186 (21.2%) | 98 (25.9%) | 88 (17.7%) |
BP lowering medication, n (%) | 460 (75.5%) | 187 (82.4%) | 273 (71.5%) |
Statin, n (%) | 229 (37.6%) | 93 (41.0%) | 136 (35.6%) |
Aspirin | 285 (32.5%) | 109 (28.8%) | 176 (35.3%) |
Warfarin | 70 (8%) | 27 (7.1%) | 43 (8.6%) |
Digoxin | 38 (6.2%) | 19 (8.4%) | 19 (5.0%) |
Aspirin + warfarin | 9 (1.5) | 4 (1.8%) | 5 (1.3%) |
Warfarin or Aspirin | 346 (56.8%) | 132 (58.1%) | 214 (56.0%) |
Risk scores | |||
CHADS2 median (IQR) | 3 (2) | 3 (2) | 2 (2) |
CHA2DS2-Vas, median (IQR) | 5 (2) | 5 (2) | 4 (2) |
HAS-BLED, median (IQR) | 3 (2) | 3 (1) | 3 (2) |
Yearly bleeding risk, n (%) | |||
- 0 to 2 | 326 (37.2%) | 169 (44.6%) | 157 (31.5%) |
-≥ 3 high risk | 551 (62.8%) | 210 (55.4%) | 341 (68.5%) |